Nuventra Pharma Sciences is now Allucent. Learn more here.

Take a deeper dive

Webinar | Pediatric Drug Development: Allometry and Other Empirical Models

This webinar covers an introduction of pediatric drug development using allometric scaling and other empirical models. Other empirical models will include Physiologically-Based Pharmacokinetics (PBPK) and Population PK (popPK).

At the end of this webinar attendees should have a better understanding of:

  • Allometry and its appropriate application to pediatric drug development
  • Simplicity of allometric scaling in comparison to other complex empirical models
  • Dose selection for first-in-pediatric clinical trials

Meet the Speaker

Iftekhar Mahmood, Ph.D.
Senior Consultant, Clinical Pharmacology and Pharmacometrics

Dr. Mahmood has more than 25 years of experience in clinical pharmacology with the FDA. He worked both in the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER). At the FDA, besides his review duties, Dr. Mahmood was involved with clinical pharmacology research (both small and large molecules) and published more than 100 research papers in peer-reviewed scientific journals. His research mainly focused on allometric scaling, modeling, sparse sampling, and pediatric drug development.

Explore Our Blog

Common Clinical Pharmacology Mistakes to Avoid in Drug Development

Drug development is a complex process where clinical pharmacology data must be generated to support regulatory approval and marketing authorization.…

Read More

How to Form a Clinical Pharmacology Strategy for your NDA, BLA, or MAA

It’s common knowledge that every approved drug on a pharmacy shelf must undergo extensive testing to demonstrate safety and efficacy.…

Read More

Benefits of Utilizing the 505(b)(2) Pathway for Prodrugs

Over the past decade, at least 30 prodrugs have been approved by the US Food and Drug Administration (FDA). It…

Read More